We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Results 1 to 5 of 18
Most popular |Most recent

Modest Rise in Healthcare Deals Despite Uncertainty

Global - January 7 2019 Dealmaking in the healthcare sector dropped 5 in 2018, to USD 308 billion, as political uncertainty and new regulations came into force. However...

Ashok Lalwani, Alan F. Zoccolillo, Jr., Hideo Norikoshi, Jane Hobson.

Megadeals and Cross-Border Listings into US and Hong Kong Dominate Global IPOs

Global - December 10 2018 Global capital raised from IPOs increased 5 despite a decline in activity levels in a year dominated by megadeals and cross-border listings into US...

David Holland, Koen V. Vanhaerents, Pablo Berckholtz, Christopher M. Bartoli, Adam B. Farlow.

Conducting Clinical Trials in Australia

Australia - March 5 2018 The clinical trials sector is a successful and growing area of Australian healthcare, strongly supported by the Australian Government. It is...

Elisabeth White.

Healthcare Deal Activity to Surge Amid Strong Market Conditions and US Tax Reform

Global - January 5 2018 Uncertainty in the wake of Brexit, the US presidential election and pending US tax reform cooled healthcare M&A activity in 2017. In 2018, however, we...

Alan F. Zoccolillo, Jr., Jane Hobson.

Australian Taxation Office: Pharmaceutical Industry Now in the Spotlight

Australia - September 13 2017 The Australian Taxation Office (ATO) has announced that it plans to closely examine the tax profiles of companies in the pharmaceutical industry in...

Elisabeth White, Dixon Hearder, John Walker, Simone Bridges.